Cheapest biotech available is AEGR, most underpriced
Market opportunity is between $900M and $3B/year for Juxtapid.
It is a $635.20/share stock for U.S. only or a $2,117/share stock with EU approval too.
No matter how you slice it, $61/share is incredibly under priced.
It will still be a 10-bagger from here within 3 years.
Careful, morons will say you are distorting the truth. Remember to subtract $68M/year out of that $3B in revenue to come out to true EARNINGS. Sure it is statistically insignificant and reduces to just pennies per share in the final analysis, and they don't know any better, but it looks more accurate, so knock off $2/share out of that $107 in revenues to come all the way down to $105 in EARNINGS.